Imperial College London
Portrait Picture

Professor Hashim Ahmed

Faculty of Medicine, Department of Surgery & Cancer

Chair in Urology (Clinical)
 
 
 
//

Contact

 

hashim.ahmed

 
 
//

Location

 

5L28Lab BlockCharing Cross Campus

//

Summary

 

Publications

Citation

BibTex format

@article{MacLennan:2017:10.1111/bju.13854,
author = {MacLennan, S and Williamson, PR and Bekema, H and Campbell, M and Ramsay, C and N'Dow, J and MacLennan, S and Vale, L and Dahm, P and Mottet, N and Lam, T and COMPACTERS, Study Group},
doi = {10.1111/bju.13854},
journal = {BJU International},
pages = {E64--E79},
title = {A core outcome set for localised prostate cancer effectiveness trials.},
url = {http://dx.doi.org/10.1111/bju.13854},
volume = {120},
year = {2017}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - OBJECTIVE: To develop a core outcome set (COS) applicable for effectiveness trials of all interventions for localised prostate cancer. Many treatments exist for localised prostate cancer, although it is unclear which offers the optimal therapeutic ratio; which is confounded by inconsistencies in the selection, definition, measurement and reporting of outcomes in clinical trials. PATIENTS, SUBJECTS AND METHODS: A list of 79 outcomes was derived from a systematic review of published localised prostate cancer effectiveness studies and semi-structured interviews with 15 patients with prostate cancer patients. A two-stage consensus process involving 118 patients and 56 international healthcare professionals (HCPs; cancer specialist nurses, urological surgeons and oncologists) was undertaken, consisting of a three-round Delphi survey followed by a face-to-face consensus panel meeting of 13 HCPs and eight patients. RESULTS: The final COS included 19 outcomes. In all, 12 apply to all interventions: death from prostate cancer, death from any cause, local disease recurrence, distant disease recurrence/metastases, disease progression, need for salvage therapy, overall quality of life, stress urinary incontinence, urinary function, bowel function, faecal incontinence, and sexual function. Seven were intervention-specific: perioperative deaths (surgery), positive surgical margin (surgery), thromboembolic disease (surgery), bothersome or symptomatic urethral or anastomotic stricture (surgery), need for curative treatment (active surveillance), treatment failure (ablative therapy), and side-effects of hormonal therapy (hormone therapy). The UK-centric participants may limit the generalisability to other countries, but trialists should reason why the COS would not be applicable. The default position should not be that a COS developed in one country will automatically not be applicable elsewhere. CONCLUSION: We have established a COS for trials of effectiveness in localised prostate
AU  - MacLennan,S
AU  - Williamson,PR
AU  - Bekema,H
AU  - Campbell,M
AU  - Ramsay,C
AU  - N'Dow,J
AU  - MacLennan,S
AU  - Vale,L
AU  - Dahm,P
AU  - Mottet,N
AU  - Lam,T
AU  - COMPACTERS,Study Group
DO  - 10.1111/bju.13854
EP  - 79
PY  - 2017///
SN  - 1464-4096
SP  - 64
TI  - A core outcome set for localised prostate cancer effectiveness trials.
T2  - BJU International
UR  - http://dx.doi.org/10.1111/bju.13854
UR  - http://hdl.handle.net/10044/1/51707
VL  - 120
ER  -
Download